When was Normunity founded?

Normunity was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Normunity located?

Normunity is headquartered in Boston, United States.

How many employees does Normunity have?

As of Sep 30, 2026, the latest employee count at Normunity is 26.

Is Normunity a funded company?

Normunity is a funded company, having raised a total of $140M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 25, 2022.

How much is Normunity worth?

The latest valuation of Normunity is $***** as of Jan 01, 2025.

When was the latest funding round of Normunity?

Normunity's latest funding was a $***** Series B round on Jan 13, 2025, with participation from 10 investors.

Where does Normunity rank among its competitors?

Normunity ranks 465th amongst 3491 active competitors, of which 1156 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Normunity?

Normunity's top competitors include BeiGene, Jazz Pharmaceuticals and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Normunity - 2026 Company Profile, Team, Funding & Competitors

Normunity is a series B company based in Boston (United States), founded in 2020 by Lieping Chen. It operates as a Developer of immunotherapies for the treatment of cancer. Normunity has raised $140M in funding from investors like Canaan, Samsara BioCapital and Enavate Sciences, with a current valuation of $*****. The company has 3491 active competitors, including 1156 funded and 812 that have exited. Its top competitors include companies like BeiGene, Jazz Pharmaceuticals and Kite Pharma.

Company Details

Developer of immunotherapies for the treatment of cancer. It is developing a pipeline of immune normalizers to restore the immune system’s intrinsic activity to identify and eliminate cancer cells. The lead program is a monoclonal antibody targeting a secreted enzyme that is highly upregulated in multiple human cancers and drives the exclusion of T-cell infiltration in immuno-sensitive tumors.

Website: normunity.com
Social
Email ID: *****@normunity.com
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Boston, United States

Stage

Series B

Total Funding

$140M in 2 rounds

Latest Funding Round

Series B, Jan 13, 2025, $*****

Post Money Valuation

$***** as on Jan 01, 2025

Investors

Canaan & 10 more

Ranked

465^th among 3491 active competitors

Employee Count

26 as on Sep 30, 2026

Similar Companies

BeiGene & 831 more

View Normunity's full profile

Normunity has raised a total funding of $140M over 2 rounds. Its first funding round was on Oct 25, 2022. Its latest funding round was a Series B round on Jan 13, 2025 for $*****. 10 investors participated in its latest round. Normunity has 11 institutional investors.

Here is the list of recent funding rounds of Normunity:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 13, 2025	8218002	Series B	3887527	1594210	6878636	7543645
Oct 25, 2022	5849054	Series A	9527869	5714568	Canaan	Taiho Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Normunity's funding rounds and investors

The founders of Normunity is Lieping Chen.

Here are the details of Normunity's key team members:

Lieping Chen: Co-Founder of Normunity.
Contact Info: 1 email address

View details of Normunity's Founder profiles and Board Members

Normunity's employee count trend

Normunity has 26 employees as of Sep 26. Here is Normunity's employee count trend over the years:

Uncover Normunity's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Normunity include BeiGene, Jazz Pharmaceuticals and Kite Pharma. Here is the list of Top 10 competitors of Normunity, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
465th	Normunity 2020, Boston (United States), Series B	Developer of immunotherapies for the treatment of cancer	$140M	Canaan, Enavate Sciences & 9 others	55/100